Inflammatory bowel disease (IBD) is associated with increased risks for genitourinary cancers, including prostate cancer and renal cell carcinoma (RCC), according to study results presented at the ...

An early-phase trial found that a personalized vaccine targeted and destroyed cancer cells in nine patients with advanced kidney cancer, effectively wiping out the disease and keeping it at bay ...

Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.

Casdatifan, a HIF-2α inhibitor, shows early clinical activity and good tolerance in patients with previously treated clear cell renal cell carcinoma.

Intended setting of use for genitourinary cancer drug approvals by tumor type, 2020-2024. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not ...

The impact of the Area Deprivation Index on immunotherapy outcomes in metastatic renal cell carcinoma (mRCC). This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This ...

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces presentations featuring the Company’s late-stage and next generation therapeutic programs at the upcoming ...

Shilpa Gupta, MD, discusses the key takeaways from the long-term outcomes of the JAVELIN Bladder 100 trial for community ...

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its planned presence at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), including three accepted ...

Santos, M. , Gomes, T. , Tortelli, A. , Castro, L. , Augustin, I. and Grosbelli, F. (2025) The Hidden Intruder: A Closer Look ...

First real-world outcomes data for ADSTILADRIN® (nadofaragene firadenovec-vncg) to be presented at 2025 ASCO Genitourinary ...

Among patients with muscle-invasive bladder cancer, adjuvant Opdivo showed a continued benefit in survival versus placebo.